Evidence-biased antidepressant prescription : overmedicalisation, flawed research, and conflicts of interest / Michael P. Hengartner.
2022
RM332 .H46 2022
Linked e-resources
Linked Resource
Concurrent users
Unlimited
Authorized users
Authorized users
Document Delivery Supplied
Can lend chapters, not whole ebooks
Details
Title
Evidence-biased antidepressant prescription : overmedicalisation, flawed research, and conflicts of interest / Michael P. Hengartner.
ISBN
9783030825874 (electronic bk.)
3030825876 (electronic bk.)
9783030825867
3030825868
3030825876 (electronic bk.)
9783030825867
3030825868
Published
Cham : Palgrave Macmillan, [2022]
Copyright
©2022
Language
English
Description
1 online resource
Item Number
10.1007/978-3-030-82587-4 doi
Call Number
RM332 .H46 2022
Dewey Decimal Classification
616.85/27061
Summary
This book addresses the over-prescribing of antidepressants in people with mostly mild and subthreshold depression. It outlines the steep increase in antidepressant prescription and critically examines the current scientific evidence on the efficacy and safety of antidepressants in depression. The book is not only concerned with the conflicting views as to whether antidepressants are useful or ineffective in various forms of depression, but also aims at detailing how flaws in the conduct and reporting of antidepressant trials have led to an overestimation of benefits and underestimation of harms. The transformation of the diagnostic concept of depression from a rare but serious disorder to an over-inclusive, highly prevalent but predominantly mild and self-limiting disorder is central to the books argument. It maintains that biological reductionism in psychiatry and pharmaceutical marketing reframed depression as a brain disorder, corroborating the overemphasis on drug treatment in both research and practice. Finally, the author goes on to explore how pharmaceutical companies have distorted the scientific literature on the efficacy and safety of antidepressants and how patient advocacy groups, leading academics, and medical organisations with pervasive financial ties to the industry helped to promote systematically biased benefit-harm evaluations, affecting public attitudes towards antidepressants as well as medical education, training, and practice. Michael P. Hengartner is a senior researcher and lecturer at the Zurich University of Applied Sciences, Switzerland. He has published over 130 peer-reviewed journal articles and four book chapters. He was an expert evaluator for the European Research Council and the World Health Organization and currently is a member of the Swiss School of Public Health, the German Society for Social Psychiatry, and the European Public Health Association.
Bibliography, etc. Note
Includes bibliographical references and index.
Access Note
Access limited to authorized users.
Source of Description
Online resource; title from PDF title page (SpringerLink, viewed December 14, 2021).
Available in Other Form
Linked Resources
Record Appears in
Table of Contents
1. Introduction: How did I get here?
2. Antidepressants in clinical practice
3. Medico-cultural context
4. Flaws in antidepressant research
5. Conflicts of interest in psychiatry
6. Solutions for reform.
2. Antidepressants in clinical practice
3. Medico-cultural context
4. Flaws in antidepressant research
5. Conflicts of interest in psychiatry
6. Solutions for reform.